NCI Payline 2026: No Cutoff, Budget Cuts, R01 Odds
Updated 7 official sources
Quick Answer: NCI has no FY2026 payline. Its policy says NCI "no longer uses paylines to determine competing grant funding selections." It does publish budget cuts: new R01s above $250,000 in direct costs are funded 17% below the study section's recommended level.
Full answer and how we checked it
NIH's Data Book shows NCI funded 6.9% of new R01 applications in FY2025 (432 of 6,278). A Grantsights pull of NIH RePORTER found 806 new NCI R01 and R37 awards in FY2026, up from 499.
This guide is for: cancer researchers looking up the NCI payline, deciding whether an R01 or R21 budget will survive NCI's FY2026 reductions, or comparing NCI's odds with other institutes after a weak FY2025.
Data note: Policy text is from NCI's FY2026 funding policies page on grants.nih.gov, read October 1, 2026. Success rates are from NIH Data Book table 206 (data last updated February 18, 2026) and table 217. Award counts, project lengths, first-year direct costs and notice dates are from a Grantsights pull of the NIH RePORTER API on October 1, 2026 (administering institute NCI, activity codes R01 and R37, award types 1 and 2, fiscal years 2024-2026). The same query can be rerun in NIH RePORTER.
In this guide
- NCI Payline Status: Selection Without a Cutoff
- NCI Budget Reductions in FY2026
- Why $250,000 Is the Line That Matters
- NCI R01 Success Rates: FY2021 to FY2025
- What NCI's FY2026 Award Record Shows
- Award Size After the Cuts
- When NCI Awards Arrive
- What NCI's Policy Page Doesn't Tell You
- Submit, Resize, or Switch: Decision Table
- Sources
- Related Guides
To compare NCI with every other institute, the NIH and NSF funding odds tracker puts each institute's FY2026 policy and its FY2021-FY2025 success rates side by side, with a CSV.
For years, NCI's percentile cutoff was the number cancer researchers tracked most closely. That number is gone. What NCI does publish now is arguably more useful for planning: exactly how much it trims each kind of new award. This page puts that policy next to NCI's funding odds and its FY2026 award record.
From Manusights, our sister product
Applying for an R01 or R21? Manusights offers an AI critique of your application against NIH's published review criteria: $149 for a new R01 or R21, $199 for a resubmission. Back within 3 business days of your upload.
Order a grant reviewNCI Payline Status: Selection Without a Cutoff
According to the NCI FY2026 funding policies (opens in a new tab), after study section review and the National Cancer Advisory Board, NCI's scientific leaders and program staff consider 7 factors:
| NCI selection factor (FY2026) | What to do about it |
|---|---|
| Scientific merit | Still the starting point; your score carries weight |
| Public health significance | State the cancer burden or patient impact in plain numbers |
| Scientific novelty | Show what changes if the aims succeed |
| Representation of the topic in NCI's portfolio | Check RePORTER for how crowded your area is |
| Investigator career stage | Confirm ESI status before review |
| Total NCI funding already held by the investigator | Expect a higher bar for well-funded labs |
| Availability of NCI funds | Timing within the fiscal year matters |
NCI adds that it may fund applications that address gaps in cancer research or propose work "that may be difficult to evaluate through peer review," and that it doesn't use predetermined targets for disease areas. NCI's page also notes that NIH is under a continuing resolution through December 11, 2026, so FY2027 terms can still change. The NIH paylines guide explains how this no-cutoff model works across institutes.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
NCI Budget Reductions in FY2026
This is the part of NCI's policy that's specific enough to plan around. Reductions apply to the study section's (Initial Review Group's) recommended level:
| FY2026 NCI application type | Reduction from recommended level |
|---|---|
| New R01 or U01, more than $250,000 direct in any budget period | 17% |
| New R01 or U01, $250,000 or less, and more than $175,000 | 8.5% |
| New R01 or U01, $175,000 or less | 6.5% |
| New R21, more than $175,000 | 8.5% |
| New R21, $175,000 or less | 6.5% |
| New P01, UM1 or R33, more than $175,000 | 17% |
| New P01, UM1 or R33, $175,000 or less | 13% |
| Competing renewals (Type 2) of R01, U01, P01, UM1, R33 | NCI Type 2 cap, no added cut |
Grantsights worked the arithmetic for three common requests:
| Requested direct costs per year | Tier | Expected award direct costs |
|---|---|---|
| $300,000 (new R01) | Over $250,000 | $249,000 |
| $225,000 (new R01) | $175,001-$250,000 | $205,875 |
| $150,000 (new R01) | $175,000 or less | $140,250 |
The common mistake is building a $300,000 R01 whose aims need every dollar. At a 17% cut, the lab gets $249,000. Plan the staffing for the post-cut number, and keep one aim that can shrink without breaking the project.
Why $250,000 Is the Line That Matters
NCI's 17% tier starts above $250,000 in direct costs in any budget period. That's the same ceiling NIH uses for modular budgets, which cover requests of up to $250,000 a year in $25,000 modules. So the policy splits NCI's new R01s into two groups:
| Budget format | Direct costs per year | FY2026 NCI cut on a new R01 |
|---|---|---|
| Modular, 7 modules or fewer | $175,000 or less | 6.5% |
| Modular, 8 to 10 modules | $200,000-$250,000 | 8.5% |
| Detailed budget | Above $250,000 in any year | 17% |
A single year above $250,000, for example an equipment purchase in year 1, moves the whole award into the 17% tier. Grantsights reads the policy as an incentive to keep year-one spikes out of a detailed budget when a modular request would cover the science. The modular budget guide explains the module rules.
NCI R01 Success Rates: FY2021 to FY2025
NIH's success-rate tables (opens in a new tab) show NCI's R01 odds fell harder in FY2025 than at most institutes.
| Fiscal year | New R01 applications / awards | New success rate | Renewal success rate | All R01 success rate |
|---|---|---|---|---|
| FY2021 | 5,807 / 696 | 12.0% | 31.7% | 12.9% |
| FY2022 | 5,379 / 691 | 12.8% | 31.6% | 13.8% |
| FY2023 | 5,221 / 722 | 13.8% | 32.1% | 14.6% |
| FY2024 | 5,499 / 584 | 10.6% | 29.1% | 11.4% |
| FY2025 | 6,278 / 432 | 6.9% | 19.7% | 7.3% |
Source: NIH Data Book table 206; "all R01" sums new, renewal and revision rows. New applications rose by 779 in FY2025 while new awards fell by 152. Across all research project grants, NIH's table 217 shows NCI at 9.6% in FY2025, against 13.7% in FY2024.
For example, NCI received 6,278 new R01 applications in FY2025, about 1.7 times NIAID's 3,613. Grantsights compared the four institutes' FY2025 new-application rates in table 206:
| Institute | New R01 applications, FY2025 | New R01 success rate |
|---|---|---|
| NCI | 6,278 | 6.9% |
| NIDDK | 2,823 | 9.0% |
| NIAID | 3,613 | 12.8% |
| NHLBI | 4,094 | 14.6% |
According to NIH, the NIH-wide R01-equivalent success rate was 13.0% in FY2025, so NCI's new-application odds were roughly half the average.
Why this page reports R01 alone: NIH's table also lists NCI R37 awards (115 in FY2025), each counted as both an application and an award, so they show a 100% rate. Adding them lifts NCI's FY2025 figure to 9.0% without changing anyone's real odds.
The R21 isn't a refuge either. NCI funded 163 of 1,990 R21 applications in FY2025 (8.2%), down from 206 of 1,696 (12.1%) in FY2024.
What NCI's FY2026 Award Record Shows
FY2026 NCI success rates aren't out yet. Grantsights pulled every FY2026 NCI R01 and R37 competing award from RePORTER on October 1, 2026:
| NCI competing R01/R37 award records | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| New (Type 1) | 647 | 499 | 806 |
| Competing renewal (Type 2) | 65 | 45 | 73 |
| New awards paid up front (multi-year funded) | 0 | 46 | 12 |
| New awards with five-year project periods | 603 | 423 | 759 |
That's the largest count of new NCI R01 awards in the three years, and it follows the 1% NIH appropriation increase that, according to NIH's FY2026 fiscal policy notice (opens in a new tab), was targeted in part to cancer. It's an award-side funding trend. If applications stayed near FY2025's 6,278, 806 new awards would still put the new-application rate near 13%, close to FY2022-FY2023 levels.
NCI also kept five-year R01s. In FY2026, 759 of 806 new awards ran five years, unlike NHLBI, where four-year awards are the default.
Award Size After the Cuts
RePORTER shows what NCI paid, after any reduction. For new awards paid one budget year at a time:
| New NCI R01/R37, single-year budgets | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Median first-year direct cost | $384,077 | $406,778 | $413,900 |
| Median total award (direct plus indirect) | $590,094 | $621,570 | $640,290 |
| Awards under $500,000 direct | 570 of 646 | 391 of 453 | 677 of 794 |
Most funded NCI R01s sit above $250,000 in direct costs, the tier that takes the 17% cut. If a median award of $413,900 had been cut 17%, the request behind it would have been about $498,700. Award records can't confirm individual requests, but the gap is a reminder to read the Notice of Award before hiring.
When NCI Awards Arrive
FY2026 new NCI R01 and R37 award notices peaked in summer: 162 in June, 174 in July, 135 in August and 117 in September. FY2025 had an early cluster instead, with 108 notices in December 2024. Timing varies by year and council round, so a quiet spring isn't a signal.
What NCI's Policy Page Doesn't Tell You
| Source | What it gives you | What it leaves out |
|---|---|---|
| NCI FY2026 policy page | Selection factors and exact budget cuts | Any score or percentile that predicts selection |
| NIH Data Book | Official new and renewal success rates | FY2026 and percentile bands |
| NIH RePORTER | Awards after cuts, lengths, notice months | Unfunded applications and original requests |
The honest read: without a payline, a 10th-percentile NCI score in FY2026 is a strong application, not a funded one. The investigator-funding factor is the one most applicants overlook. A PI with several active NCI awards should expect a higher bar than an ESI with the same score.
Submit, Resize, or Switch: Decision Table
| Your situation | Best next action |
|---|---|
| New R01 planned near $260,000 direct | Model both tiers; at $250,000 the cut is 8.5%, above it 17% |
| R21 chosen because it seems easier | Skip that logic; NCI's FY2025 R21 rate was 8.2% |
| Scored FY2025 A0 that missed | Resubmit; FY2026 new-award counts rose to 806 |
| Renewal coming due | Renewals avoid the added cut; submit with time for one A1 |
| ESI applicant | Confirm ESI status; career stage is a listed factor |
Use the summary statement guide and the resubmission guide for the A1. Compare odds with the NIAID R01 success-rate page and the NIDDK payline page, and search cancer-related funding beyond NCI in Grantsights grant search.
Sources
- NCI FY2026 funding policies and considerations (opens in a new tab)
- NIH Data Book success-rate tables (opens in a new tab) (tables 206 and 217)
- NIH success rate definition (opens in a new tab)
- NOT-OD-26-059, Notice of Fiscal Policies in Effect for FY 2026 (opens in a new tab)
- NOT-OD-26-131, NIH Operates Under a Continuing Resolution (opens in a new tab)
- NIH RePORTER (opens in a new tab) and the RePORTER API (opens in a new tab)
Related Guides
Frequently Asked Questions
What is the NCI payline for 2026?
NCI no longer has one. Its FY2026 funding policy says that, in alignment with NIH funding policies, NCI no longer uses paylines to determine competing grant funding selections. Scientific leaders and program staff weigh merit, public health significance, novelty, portfolio representation, career stage, existing NCI funding and available funds.
How much does NCI cut new R01 budgets?
Under the FY2026 policy, a new R01 with more than $250,000 in direct costs in any budget period is generally funded 17% below the study section's recommended level. New R01s at or under $250,000 are cut 6.5% when at or under $175,000 and 8.5% when above it. Competing renewals are funded at the NCI Type 2 cap with no added reduction.
What was the NCI R01 success rate in FY2025?
NIH Data Book table 206 shows NCI funded 432 of 6,278 new R01 applications in FY2025 (6.9%) and 47 of 239 renewals (19.7%). Counting all R01 applications, the rate was 7.3%, down from 11.4% in FY2024 and 14.6% in FY2023.
What is the NCI R21 success rate?
NIH's table shows NCI funded 163 of 1,990 R21 applications in FY2025, an 8.2% success rate, down from 12.1% in FY2024. New R21s are also cut 6.5% or 8.5% from the recommended level under the FY2026 policy.
Did NCI fund more R01s in FY2026?
The award record says yes. A Grantsights pull of NIH RePORTER on October 1, 2026 found 806 new NCI R01 and R37 awards in FY2026, against 499 in FY2025 and 647 in FY2024. NIH hasn't published FY2026 application counts, so the success rate isn't known yet.
Last updated October 1, 2026. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NEI Payline 2026: No Cutoff and a 12.8% New R01 Rate
NEI publishes no FY2026 payline or score cutoff. Its new R01 success rate fell from 23.6% to 12.8% in FY2025, while renewals held at 32.6%. See the data.
NHLBI Payline FY2026: No Cutoff, R01 Odds and Data
NHLBI has no FY2026 payline. NIH tables show it funded 14.6% of new R01 applications in FY2025, and 585 new R01s appear in FY2026 RePORTER records.
NIA Payline 2026: No Cutoff, 5.0% New R01 Odds
NIA has published no payline since FY2024, when general R01s funded to the 16th percentile. Its new R01 success rate fell to 5.0% in FY2025. See the data.
NIBIB Payline 2026: No Cutoff and a 16.1% New R01 Rate
NIBIB has no FY2026 payline. It cuts parent R01 budgets 10% to 20% and caps them at 4 years. Its new R01 success rate was 16.1% in FY2025. See the data.
NICHD Payline 2026: No Cutoff, 14.1% New R01 Odds
NICHD publishes no payline. It funded 14.1% of new R01s in FY2025 and cuts new R01 budgets 14% on average. See the rules and five years of odds.
NIDA Payline 2026: No Cutoff, 11.5% New R01 Odds
NIDA has no payline. It funded 11.5% of new R01s in FY2025 and caps renewal growth at 10% without strong justification. See NIDA's rules and odds.